A Systematic Review and Network Meta‐Analysis of Regorafenib and TAS‐102 in Refractory Metastatic Colorectal Cancer

导出原文传递

翻译打印收藏纠错

作者： Sonbol Mohamad Bassam ^[1] ; Benkhadra Raed ^[2] ; Wang Zhen ^[3] ; Firwana Belal ^[4] ; Walden Daniel J. ^[5] ; Mody Kabir ^[6] ; Hubbard Joleen M. ; Murad M. Hassan ; Ahn Daniel H. ; Bekaii‐Saab Tanios

作者单位： Evidence‐based Practice Center, Mayo ClinicRochester,Minnesota,USA ^[1] Heartland Cancer Research NCORP, Missouri Baptist Medical CenterSt Louis,Missouri,USA ^[2] Allegheny General HospitalPittsburgh,Pennsylvania,USA ^[3] Mayo Clinic Cancer Center, Mayo ClinicJacksonville,Florida,USA ^[4] Mayo Clinic Cancer Center, Mayo ClinicRochester,Minnesota,USA ^[5] Mayo Clinic Cancer Center, Mayo ClinicPhoenix,Arizona,USA ^[6]

关键词 TAS‐102 Regorafenib Refractory metastatic colorectal cancer

发布时间 2020-02-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交